

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

PHILIPP BROTHERS CHEMICALS INC

Form 10-Q

November 14, 2002

=====

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

* QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2002

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____.

Commission File Number 333-64641

Philipp Brothers Chemicals, Inc.
(Exact name of registrant as specified in its charter)

New York
(State or other jurisdiction
of incorporation or organization)

13-1840497
(I.R.S. Employer
Identification No.)

One Parker Plaza, Fort Lee, New Jersey 07024
(Address of principal executive offices) (Zip Code)

(201) 944-6020
(Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes *

No

Number of shares of each class of common stock outstanding as of September 30, 2002:

Class A Common Stock, \$.10 par value: 12,600.00
Class B Common Stock, \$.10 par value: 11,888.50

* By virtue of Section 15(d) of the Securities Act of 1934, the Registrant is not subject to such filing requirements and not required to file this

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

Quarterly Report, but has provided all such reports as if so required during the preceding 12 months.

=====

PHILIPP BROTHERS CHEMICALS, INC.

TABLE OF CONTENTS

	Page

PART I FINANCIAL INFORMATION (UNAUDITED)	
Item 1. Condensed Financial Statements	3
Condensed Consolidated Balance Sheets	4
Condensed Consolidated Statements of Operations and Comprehensive Income	5
Condensed Consolidated Statements of Changes in Stockholders' Deficit	6
Condensed Consolidated Statements of Cash Flows	7
Notes to Condensed Consolidated Financial Statements	8
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3. Quantitative and Qualitative Disclosures About Market Risk	25
Item 4. Control and Procedures	25
PART II OTHER INFORMATION	
Item 1. Legal Proceedings	26
Item 5. Other Information	26
Item 6. Exhibits and Reports on Form 8-K	26
SIGNATURES	27

2

This Form 10-Q contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company's actual results could differ materially from those set forth in the forward-looking statements. Certain factors that might cause such a difference are discussed in the Company's Annual Report on Form 10-K for its fiscal year ended June 30, 2002 and/or throughout this Form 10-Q and in particular in Item 2 of Part I of this Form 10-Q under the caption "Certain Factors Affecting Future Operating Results." Unless the context otherwise requires, references in this report to the "Company" refers to the Company and/or one or more of its subsidiaries, as applicable.

PART I -- FINANCIAL INFORMATION

Item 1. Condensed Financial Statements

3

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

PHILIPP BROTHERS CHEMICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

(In Thousands)

	September 30, 2002	June 30, 2002
	-----	-----
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 8,653	\$ 6,419
Trade receivables, less allowance for doubtful accounts of \$2,858 at September 30, 2002 and \$2,927 at June 30, 2002	60,495	65,161
Other receivables	3,041	3,912
Inventories	89,962	93,517
Prepaid expenses and other current assets	14,235	15,965
	-----	-----
TOTAL CURRENT ASSETS	176,386	184,974
PROPERTY, PLANT AND EQUIPMENT, net	83,456	84,730
INTANGIBLES	12,840	13,200
OTHER ASSETS	12,601	13,540
	-----	-----
	\$ 285,283	\$ 296,444
	=====	=====
LIABILITIES AND STOCKHOLDERS' DEFICIT		
CURRENT LIABILITIES:		
Cash overdraft	\$ 1,967	\$ 7,767
Loans payable to banks	31,086	41,535
Current portion of long-term debt	10,038	8,851
Accounts payable	50,780	42,280
Accrued expenses and other current liabilities	37,864	34,080
	-----	-----
TOTAL CURRENT LIABILITIES	131,735	134,513
LONG-TERM DEBT	134,036	136,641
OTHER LIABILITIES	28,166	29,877
	-----	-----
TOTAL LIABILITIES	293,937	301,031
	-----	-----
COMMITMENTS AND CONTINGENCIES		
REDEEMABLE SECURITIES:		
Series B and C preferred stock	58,725	56,602
	-----	-----
STOCKHOLDERS' DEFICIT:		
Series A preferred stock	521	521
Common stock	2	2
Paid-in capital	740	740

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

Retained earnings	(51,932)	(49,652)
Accumulated other comprehensive (loss) income -		
(loss) gain on derivative instruments	(21)	1,062
cumulative currency translation adjustment	(16,689)	(13,862)
	-----	-----
TOTAL STOCKHOLDERS' DEFICIT	(67,379)	(61,189)
	-----	-----
	\$ 285,283	\$ 296,444
	=====	=====

See notes to unaudited Condensed Consolidated Financial Statements.

4

PHILIPP BROTHERS CHEMICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(Unaudited)

For the Three Months Ended September 30, 2002 and 2001

(In Thousands)

	2002	2001
	-----	-----
NET SALES	\$ 97,041	\$ 94,659
COST OF GOODS SOLD	75,237	74,194
	-----	-----
GROSS PROFIT	21,804	20,465
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	17,446	19,056
	-----	-----
OPERATING INCOME	4,358	1,409
OTHER:		
Interest expense	4,504	4,643
Interest income	(126)	(70)
Other (income)/expense, net	(310)	(195)
	-----	-----
INCOME (LOSS) BEFORE INCOME TAXES	290	(2,969)
PROVISION (BENEFIT) FOR INCOME TAXES	447	(604)
	-----	-----
NET LOSS	(157)	(2,365)
OTHER COMPREHENSIVE (LOSS) INCOME-		
(Loss) gain on derivative instruments	(1,083)	145
Change in currency translation adjustment	(2,827)	(1,566)
	-----	-----
COMPREHENSIVE LOSS	\$ (4,067)	\$ (3,786)
	=====	=====

See notes to unaudited Condensed Consolidated Financial Statements.

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

5

PHILIPP BROTHERS CHEMICALS, INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT
 (Unaudited)

For the Three Months Ended September 30, 2002

(In Thousands)

	Preferred Stock	Common Stock		Paid-in Capital
	Series A	Class "A"	Class "B"	
BALANCE, JULY 1, 2002	\$ 521	\$ 1	\$ 1	\$ 740
Accretion of redeemable preferred securities to fair market value				
Dividends on Series B and C redeemable preferred stock				
Loss on derivative instruments				
Foreign currency translation adjustment				
Net loss				
BALANCE, SEPTEMBER 30, 2002	\$ 521 =====	\$ 1 =====	\$ 1 =====	\$ 740 =====

See notes to unaudited Condensed Consolidated Financial Statements.

6

PHILIPP BROTHERS CHEMICALS, INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

For the Three Months Ended September 30, 2002 and 2001

(In Thousands)

	2002	2001
OPERATING ACTIVITIES:		
Net loss	\$ (157)	\$ (2,365)

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization	3,937	4,158
Other	1,259	789
Changes in operating assets and liabilities:		
Accounts receivable	3,955	5,525
Inventories	1,441	(4,383)
Prepaid expenses and other current assets	1,469	2,606
Other assets	(187)	(815)
Accounts payable	8,870	(1,334)
Accrued expenses and other current liabilities	2,987	872
NET CASH PROVIDED BY OPERATING ACTIVITIES	23,574	5,053
INVESTING ACTIVITIES:		
Capital expenditures	(4,017)	(3,626)
Other investing	320	79
NET CASH USED IN INVESTING ACTIVITIES	(3,697)	(3,547)
FINANCING ACTIVITIES:		
Cash overdraft	(5,800)	99
Net increase (decrease) in short-term debt	(10,387)	1,917
Proceeds from long-term debt	--	11
Payments of long-term debt	(1,468)	(1,073)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(17,655)	954
EFFECT OF EXCHANGE RATE CHANGES ON CASH	12	52
NET INCREASE IN CASH AND CASH EQUIVALENTS	2,234	2,512
CASH AND CASH EQUIVALENTS at beginning of period	6,419	14,845
CASH AND CASH EQUIVALENTS at end of period	\$ 8,653	\$ 17,357

See notes to unaudited Condensed Consolidated Financial Statements.

PHILIPP BROTHERS CHEMICALS, INC. AND SUBSIDIARIES
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 (Unaudited)
 (In Thousands)

1. General

In the opinion of Philipp Brothers Chemicals, Inc. (the "Company"), the accompanying unaudited condensed consolidated financials statements contain all adjustments (consisting only of normal recurring adjustments) necessary to present fairly its financial position as of September 30, 2002 and its results

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

of operations and cash flows for the three months ended September 30, 2002 and 2001.

The condensed consolidated balance sheet as of June 30, 2002 was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles. Additionally, it should be noted that the accompanying condensed consolidated financial statements and notes thereto have been prepared in accordance with accounting standards appropriate for interim financial statements. While the Company believes that the disclosures presented are adequate to make the information contained herein not misleading, it is suggested that these financial statements be read in conjunction with the Company's consolidated financial statements for the year ended June 30, 2002.

Certain prior year amounts in the accompanying condensed consolidated financial statements and related notes have been reclassified to conform to the fiscal 2003 presentation.

The results of operations for the three months ended September 30, 2002 may not be indicative of results for the full year.

Effective July 1, 2002 the Company adopted Statements of Financial Accounting Standards No. 141 "Business Combinations" ("SFAS No. 141") and No. 142 "Goodwill and Other Intangibles" ("SFAS No. 142"). SFAS No. 141 requires that the purchase method of accounting be used for all business combinations initiated after June 30, 2001. The statement also establishes specific criteria for recognition of intangible assets separately from goodwill. The statement requires that goodwill and indefinite lived intangible assets no longer be amortized and be tested for impairment at least annually. The amortization period of intangible assets with finite lives will no longer be limited to forty years. The Company has no goodwill, but has assessed the useful lives of its intangible assets. The adoption of SFAS No. 141 and No. 142 did not result in an impact on the Company's financial statements.

Effective July 1, 2002 the Company adopted Statement of Financial Accounting Standards No. 143 "Accounting for Asset Retirement Obligations" ("SFAS No. 143"). SFAS No. 143 established accounting standards for the recognition and measurement of an asset retirement obligation and its associated asset retirement cost. The Company has reviewed its tangible long-lived assets for associated asset retirement obligations ("AROs") in accordance with SFAS No. 143. The Company has not recognized liabilities associated with AROs since the associated assets have indeterminate useful lives.

Effective July 1, 2002 the Company adopted Statement of Financial Accounting Standard No. 144 "Accounting for Impairment or Disposal of Long-Lived Assets" ("SFAS No. 144"). SFAS No. 144 addresses significant issues relating to the implementation of FASB Statement No. 121 "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of" ("SFAS No. 121"), and the development of a single accounting model, based on the framework established in SFAS No. 121, for long-lived assets to be disposed of by sale, whether previously held and used or newly acquired. The adoption of SFAS No. 144 did not result in an impact on the Company's financial statements.

Effective July 1, 2002 the Company adopted Statement of Financial Accounting Standards No. 145, "Rescission of SFAS Nos. 4, 44 and 64, Amendment of SFAS 13, and Technical Corrections" ("SFAS No. 145"). Under the current rules, SFAS No. 4, "Reporting Gains and Losses from Extinguishment of Debt," requires that all gains and losses from the extinguishment of debt be classified as extraordinary on the Company's consolidated statement of operations, net of applicable taxes. SFAS No. 145 rescinds the automatic classification as extraordinary and requires that the Company evaluate whether the gains or losses qualify as extraordinary under Accounting Principles Board Opinion No. 30,

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

"Reporting the Results of Operations- Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions." The adoption of SFAS No. 145 did not result in an impact on the Company's financial statements.

8

PHILIPP BROTHERS CHEMICALS, INC. AND SUBSIDIARIES
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 (Unaudited)
 (In Thousands)

In June 2002, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 146, "Accounting for Costs Associated with Exit or Disposal Activities" ("SFAS No. 146"). SFAS No. 146 requires that a liability for a cost associated with an exit or disposal activity be recognized and measured initially at fair value when the liability is incurred rather than at the date of a commitment to an exit or disposal plan. Costs covered by SFAS No. 146 include lease termination costs and certain employee severance costs that are associated with a restructuring, discontinued operation, plant closing or other exit or disposal activity. SFAS No. 146 is effective for exit or disposal activities that are initiated after December 31, 2002. The Company is currently assessing the impact of this statement.

2. Reclassifications

Freight and warehousing expenses of \$6,598, \$6,994, \$6,428 and \$9,245 for the three months ended September 30, 2001, December 31, 2001, March 31, 2002 and June 30, 2002, respectively, are being reclassified from selling, general and administrative expenses to cost of goods sold on the Company's condensed consolidated statements of operations and comprehensive income. This reclassification had no impact on net sales, operating income (loss) or net loss for each of the periods presented below. Results for the prior fiscal year are as follows:

	3 Months Ended September 30, 2001	3 Months Ended December 31, 2001	3 Months Ended March 31, 2002	3 Months Ended June 30, 2002	
	-----	-----	-----	-----	-----
Net Sales	\$ 94,659	\$ 97,987	\$ 96,310	\$ 99,857	
Gross Profit	20,465	24,295	16,539	5,167	
Operating Income (Loss)	1,409	4,614	(3,729)	(23,958)	
Net (Loss)	(2,365)	(1,699)	(9,072)	(38,634)	

3. Risks and Uncertainties

As of September 30, 2002 (after giving effect to the amendment referred to below), the Company was in compliance with the financial covenants included in its amended senior credit facility ("credit agreement" or "facility") with its lending banks, for which PNC Bank serves as agent. The credit agreement was amended in October 2002 to: waive noncompliance with financial covenants as of June 30, 2002; amend financial covenants prospectively until maturity; amend the borrowing base formula and also reduce maximum availability under the revolving credit portion of the facility from \$70 million to \$55 million; limit borrowings under the capital expenditure line of the facility to the current outstanding balance of \$5.8 million; and increase the interest rate to 1.5% to 1.75% per

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

annum over the base rate (as defined in the agreement). Management believes that the reduced maximum availability and the revised borrowing base formula under the revolving credit portion of the facility will not adversely affect the Company's ability to meet its cash requirements during fiscal 2003.

The Company's ability to fund its fiscal 2003 operating plan relies upon continued availability of the credit agreement which, in turn, requires the Company to maintain compliance with the amended financial covenants. The Company believes that it will be able to comply with the terms of the amended covenants based on its forecasted operating plan for 2003. In the event of adverse operating results and resultant violation of the covenants during fiscal 2003, the Company cannot be certain it will be able to obtain waivers or amendments on favorable terms, if at all.

9

PHILIPP BROTHERS CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(In Thousands)

In addition, the Company's credit agreement and its note payable to Pfizer, Inc. mature in November 2003 and March 2004, respectively. The Company's management has undertaken actions to improve the Company's operating performance and overall liquidity in order to reduce debt levels and allow for ultimate refinancing of this debt in fiscal 2004. These actions include cost reduction activities, working capital improvement programs, shutdown of unprofitable operations, deferral and forbearance of certain obligations to Pfizer, and possible sale of certain business operations and other assets. These actions are ongoing and will continue to be re-evaluated during fiscal 2003.

The issue of the potential for increased bacterial resistance to certain antibiotics used in certain food-producing animals is the subject of discussions on a worldwide basis and, in certain instances, has led to government restrictions on the use of antibiotics in these food-producing animals. The sale of feed additives containing antibiotics is a material portion of the Company's business. Should regulatory or other developments result in further restrictions on the sale of such products, it could have a material adverse impact on the Company's financial position, results of operations and cash flows.

4. Inventories

Inventories are valued at the lower of cost or market. Cost is determined principally under the first-in, first-out (FIFO) and average cost methods; however, certain subsidiaries of the Company use the last-in, first-out (LIFO) method for valuing inventories. Obsolete or unsaleable inventory is reflected at its estimated net realizable value. Inventory costs include materials, direct labor and manufacturing overhead.

Inventories consist of the following at September 30, 2002 and June 30, 2002:

	September 30, 2002	June 30, 2002
	-----	-----
Raw materials	\$22,277	\$23,524
Work-in-process	1,879	2,098
Finished goods	65,806	67,895
	-----	-----
Total inventory	\$89,962	\$93,517

=====

=====

5. Restructuring and Asset Writedowns

The Company's Odda, Norway operation has suffered operating losses during fiscal years 2002 and 2001. During the third quarter of fiscal year 2002 the Company decided to cease production of two of Odda's three primary products as of June 30, 2002, and focus its resources on the remaining product line. During the fourth quarter of fiscal year 2002, due to further deterioration of the Odda business, the Company's review of certain long-lived assets of Odda for impairment, under the scenarios of continuing production of Odda's remaining primary product or complete shutdown of the Odda operation, resulted in the Company recording an impairment charge.

During fiscal 2002 Odda incurred restructuring charges and terminated approximately 120 employees. An accrual of \$824 for restructuring charges still to be paid at June 30, 2002 remained on the Company's balance sheet at June 30, 2002. An accrual of \$770 for restructuring costs still to be paid at September 30, 2002 remains on the Company's balance sheet at September 30, 2002. The Company anticipates that by the end of January 2003 substantially all of the remaining restructuring costs will be paid.

During the first quarter of fiscal 2003 Odda reduced production of its primary product, dicyandiamide, pending market acceptance of its calcium oxide, a by-product of the manufacturing process. In November 2002, the Company announced a temporary shutdown of the Odda operation due to continuing operating losses, higher than planned operating costs, and delays in the market acceptance of calcium oxide. Various alternatives are under consideration by the Company.

10

PHILIPP BROTHERS CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(In Thousands)

6. Contingencies

(a) Litigation:

On or about April 17, 1997, the Company and CP Chemicals, Inc. ("CP") were served with a complaint filed by Chevron USA, Inc. ("Chevron") in the United States District Court for the District of New Jersey, alleging that operations of CP at its Sewaren plant affected adjoining property owned by Chevron and that Philipp Brothers, as the parent of CP, is also responsible to Chevron. In July 2002, a phased settlement agreement was reached under which the Company and another defendant will, subject to certain conditions, take title to the property, subject to a period of due diligence investigation of the property. The Company's portion of the settlement for past costs and expenses is \$495 and was included in selling, general and administrative expenses in the June 30, 2002 statement of operations and comprehensive income, and was paid in July 2002. The Company and the other defendant will, if the sale becomes final, share equally in the costs of remediation. While the costs cannot be estimated at this time, the Company believes the costs will not be material and insurance recoveries will be available to offset some of those costs.

The Company's Phibro-Tech subsidiary was named in 1993 as a potentially responsible party ("PRP") in connection with an action commenced under the federal Comprehensive Environmental Response, Compensation, and Liability Act ("CERCLA") by the United States Environmental Protection Agency (the "EPA"),

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

involving a former third-party fertilizer manufacturing site in Jericho, South Carolina. An agreement has been reached under which the Company has agreed to contribute up to \$900 of which \$500 has been paid as of September 30, 2002. Some recovery from insurance and other sources is expected. The Company has also accrued its best estimate of any future costs.

The Company and its subsidiaries are a party to a number of claims and lawsuits arising in the normal course of business, including patent infringement, product liabilities and governmental regulation concerning environmental and other matters. Certain of these actions seek damages in various amounts.

All such claims are being contested, and management believes the resolution of these matters will not materially affect the consolidated financial position, results of operations or cash flows of the Company.

(b) Environmental Remediation:

The Company's domestic subsidiaries are subject to various federal, state and local environmental laws and regulations that govern the management of chemical wastes. The most significant regulation governing the Company's recycling activities is the Resource Conservation and Recovery Act of 1976 ("RCRA"). The Company has been issued final RCRA "Part B" permits to operate as hazardous waste treatment and storage facilities at its facilities in Santa Fe Springs, California; Garland, Texas; Joliet, Illinois; Sumter, South Carolina; and Sewaren, New Jersey. The Company has ceased operations at its Union City, California facility. Costs accrued for closure were \$350 as of September 30, 2002.

On or about November 15, 2001, the Company was advised by the State of California that the State intended to file a civil complaint against the Company for alleged violations arising out of operations at the Santa Fe Springs, California facility. The Company is engaged in negotiations with the State of California at this time. The amount of any penalty that may be assessed cannot be determined at this time, but is not expected to be material.

On or about April 5, 2002, the Company was served, as a potentially responsible party, with an information request from the United States Environmental Protection Agency relating to a third-party superfund site in Rhode Island. The Company is investigating the matter, which relates to events in the 1950's and 1960's.

In connection with applying for RCRA "Part B" permits, the Company has been required to perform extensive site investigations at certain of its operating facilities and inactive sites to identify possible contamination and to provide the regulatory authorities with plans and schedules for remediation. Some soil and groundwater contamination has been identified at several plant sites and will require corrective action over the next several years.

11

PHILIPP BROTHERS CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(In Thousands)

Based upon information available, management estimates the cost of further investigation and remediation of identified soil and groundwater problems at operating sites, closed sites and third-party sites (including Jericho litigation) to be approximately \$2,025, which is included in current and

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

long-term liabilities in the September 30, 2002 condensed consolidated balance sheet.

7. Business Segments

The Company has four reportable segments--Animal Health and Nutrition, Industrial Chemicals, Distribution and All Other. Reportable segments have been determined primarily on the basis of the nature of products and services and certain similar operating units have been aggregated. The Company's Animal Health and Nutrition segment manufactures and markets a broad range of feed additive products including trace minerals, anticoccidials, antibiotics, vitamins, vitamin premixes and other animal health products. The Company's Industrial Chemicals segment manufactures and markets pigments and other mineral products. Certain of these products include copper oxide, which is produced by the Company's recycling operation, mineral oxides, and alkaline etchants. The Company's Distribution segment markets and distributes a variety of industrial, specialty and fine organic chemicals and intermediates produced primarily by third parties. The Company's All Other segment manufactures and markets a variety of specialty custom chemicals, and copper-based fungicides, as well as providing management and recycling of coal combustion residues.

Segment data for the three months ended September 30, 2002 and 2001 is as follows:

Three Months Ended September 30, 2002	Animal Health & Nutrition	Industrial Chemicals	Distribution	All Other
Revenues -external customers	\$ 59,976	\$ 17,322	\$ 9,573	\$ 10,
-intersegment	927	2,893	351	
Total revenues	\$ 60,903	\$ 20,215	\$ 9,924	\$ 10,
Operating income/(loss)	\$ 9,702	\$ (2,110)	\$ 743	\$

Three Months Ended September 30, 2001	Animal Health & Nutrition	Industrial Chemicals	Distribution	All Other
Revenues -external customers	\$ 57,943	\$ 17,345	\$ 9,435	\$ 9,
-intersegment	1,410	3,666	554	
Total revenues	\$ 59,353	\$ 21,011	\$ 9,989	\$ 9,
Operating income/(loss)	\$ 7,365	\$ (4,200)	\$ 838	\$

8. Consolidating Financial Statements

In June 1998, the Company issued \$100 million in Senior Subordinated Notes due 2008 (the "Notes"). In connection with the issuance of these Notes, the Company's U.S. Subsidiaries fully and unconditionally guaranteed such Notes on a joint and several basis. Foreign subsidiaries do not presently guarantee the Notes.

PHILIPP BROTHERS CHEMICALS, INC. AND SUBSIDIARIES
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 (Unaudited)
 (In Thousands)

The following consolidating financial data summarizes the assets, liabilities and results of operations and cash flows of the Parent, Guarantors and Non-Guarantor Subsidiaries. The Parent is Philipp Brothers Chemicals, Inc. ("PBC"). The U.S. Guarantor Subsidiaries include all domestic subsidiaries of PBC including the following: C.P. Chemicals, Inc., Phibro-Tech, Inc., Mineral Resource Technologies, Inc., Prince Agriproducts, Inc., The Prince Manufacturing Company, Phibrochem, Inc., Phibro Chemicals, Inc., Western Magnesium Corp., Phibro Animal Health Holdings, Inc. and Phibro Animal Health U.S., Inc. The U.S. and foreign Guarantor and Non-Guarantor Subsidiaries are directly or indirectly wholly owned as to voting stock by PBC.

Investments in subsidiaries are accounted for by the Parent using the equity method. Income tax expense (benefit) is allocated among the consolidating entities based upon taxable income (loss) by jurisdiction within each group.

The principal consolidation adjustments are to eliminate investments in subsidiaries and intercompany balances and transactions. Separate financial statements of the U.S. Guarantor Subsidiaries and the Non-Guarantor Subsidiaries are not presented because management has determined that such financial statements would not be material to investors.

PHILIPP BROTHERS CHEMICALS, INC.
 CONDENSED CONSOLIDATING BALANCE SHEET (Unaudited)
 As of September 30, 2002
 (In Thousands)

	Parent	U.S. Guarantor Subsidiaries	Foreign Subsidiaries Non-Guarantors
Assets			
Current Assets:			
Cash and cash equivalents	\$ 43	\$ 1,758	\$ 6,852
Trade receivables	3,433	27,557	29,505
Other receivables	393	880	1,768
Inventory	2,772	48,467	38,723
Prepaid expenses and other	1,724	767	11,744
Total current assets	8,365	79,429	88,592
Property, plant & equipment, net	508	30,015	52,933

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

Intangibles	32	1,438	11,370
Investment in subsidiaries	77,824	3,621	--
Intercompany	68,146	(37,483)	1,938
Other assets	9,538	1,788	1,275
	<hr/>		
Total assets	\$ 164,413	\$ 78,808	\$ 156,108
	<hr/>		
Liabilities and Stockholders' Deficit			
Current Liabilities:			
Cash overdraft	\$ 350	\$ 1,617	\$ --
Loan payable to banks	28,064	--	3,022
Current portion of long term debt	3,507	493	6,038
Accounts payable	1,560	31,933	17,287
Accrued expenses and other	9,728	7,514	20,622
	<hr/>		
Total current liabilities	43,209	41,557	46,969
Long term debt	127,380	(67,658)	106,915
Other liabilities	2,478	5,199	20,489
	<hr/>		
Total liabilities	173,067	(20,902)	174,373
	<hr/>		
Redeemable securities:			
Series B and C preferred stock	58,725	--	--
	<hr/>		
Stockholders' Deficit			
Series A preferred stock	521	--	--
Common stock	2	32	--
Paid in capital	740	110,885	8,166
Retained earnings	(51,932)	(10,921)	(10,008)
Accumulated other comprehensive (loss) income-			
loss on derivative instruments	(21)	(311)	290
cumulative currency translation adjustment	(16,689)	25	(16,713)
	<hr/>		
Total stockholders' deficit	(67,379)	99,710	(18,265)
	<hr/>		
Total liabilities and deficit	\$ 164,413	\$ 78,808	\$ 156,108
	<hr/>		

14

PHILIPP BROTHERS CHEMICALS, INC.
CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS (Unaudited)
For The Three Months Ended September 30, 2002
(In Thousands)

U.S. Guarantor Foreign
Subsidiaries

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

	Parent	Subsidiaries	Non-Guarantors
Net sales	\$ 7,108	\$56,217	\$ 36,480
Cost of goods sold	5,787	42,813	29,401
Gross profit	1,321	13,404	7,079
Selling, general, and administrative expenses	4,358	7,474	5,614
Operating (loss) income	(3,037)	5,930	1,465
Interest expense	386	812	3,306
Interest income	(1)	--	(125)
Other expense	97	139	(546)
Intercompany allocation	(4,168)	4,168	--
Loss (profit) relating to subsidiaries	806	--	--
(Loss) income before income taxes	(157)	811	(1,170)
Provision (benefit) for income taxes	--	77	370
Net (loss) income	\$ (157)	\$ 734	\$ (1,540)

15

PHILIPP BROTHERS CHEMICALS INC.
CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS (Unaudited)
For the Three Months Ended September 30, 2002
(In Thousands)

	Parent	U.S. Guarantor Subsidiaries	Foreign Subsidiaries Non-Guarantors
Operating activities:			
Net (loss) income	\$ (157)	\$ 734	\$ (1,540)
Adjustments to reconcile net (loss) income to cash provided by operating activities:			
Depreciation and amortization	355	1,361	2,221
Other	95	(548)	1,712
Changes in operating assets and liabilities:			
Accounts receivable	(306)	1,702	2,559
Inventory	(65)	(3,553)	5,059
Prepaid expenses and other	1,285	1,669	(1,485)
Other assets	(154)	567	(600)
Intercompany	6,000	(795)	(4,399)

15

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

Accounts payable	536	7,137	1,197
Accrued expenses and other	2,322	(1,568)	2,233

Net cash provided by operating activities	9,911	6,706	6,957

Investing activities:			
Capital expenditures	(172)	(1,572)	(2,273)
Other investing	--	--	320

Net cash used in investing activities	(172)	(1,572)	(1,953)

Financing activities:			
Cash overdraft	(226)	(3,885)	(1,689)
Net decrease in short term debt	(9,927)	--	(460)
Payments of long term debt	--	(136)	(1,332)

Net cash (used in) provided by financing activities	(10,153)	(4,021)	(3,481)

Effect of exchange rate changes on cash	--	(7)	19

Net (decrease) increase in cash and cash equivalents	(414)	1,106	1,542

Cash and cash equivalents at beginning of year	457	652	5,310

Cash and cash equivalents at end of year	\$ 43	\$ 1,758	\$ 6,852
=====			

16

PHILIPP BROTHERS CHEMICALS, INC.
 CONDENSED CONSOLIDATING BALANCE SHEET (Unaudited)
 As of June 30, 2002
 (In Thousands)

	Parent	U.S. Guarantor Subsidiaries	Foreign Subsidiaries Non-Guarantors

Assets			
Current Assets:			
Cash and cash equivalents	\$ 457	\$ 130	\$ 5,832
Trade receivables	3,150	28,671	33,340
Other receivables	392	855	2,665
Inventory	2,707	44,929	45,881
Prepaid expenses and other	3,010	2,460	10,495

Total current assets	9,716	77,045	98,213

16

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

Property, plant & equipment, net	409	29,781	54,540
Intangibles	32	1,495	11,673
Investment in subsidiaries	82,540	3,621	--
Intercompany	73,359	(36,074)	(5,240)
Other assets	9,738	1,918	1,884
Total assets	\$ 175,794	\$ 77,786	\$ 161,070
Liabilities and Stockholders' Deficit			
Current Liabilities:			
Cash overdraft	\$ 576	\$ 5,502	\$ 1,689
Loan payable to banks	37,991	--	3,544
Current portion of long term debt	3,216	530	5,105
Accounts payable	1,024	24,716	16,540
Accrued expenses and other	7,579	8,092	18,409
Total current liabilities	50,386	38,840	45,287
Long term debt	127,643	(68,271)	109,314
Other liabilities	2,352	6,156	21,369
Redeemable securities:			
Series B and C preferred stock	56,602	--	--
Stockholders' Deficit			
Series A preferred stock	521	--	--
Common stock	2	32	--
Paid in capital	740	110,885	8,166
Retained earnings	(49,652)	(10,271)	(9,852)
Accumulated other comprehensive income (loss)- gain on derivative instruments	1,062	384	678
cumulative currency translation adjustment	(13,862)	31	(13,892)
Total stockholders' deficit	(61,189)	101,061	(14,900)
Total liabilities and deficit	\$ 175,794	\$ 77,786	\$ 161,070

17

PHILIPP BROTHERS CHEMICALS, INC.
 CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS (Unaudited)
 For The Three Months Ended September 30, 2001
 (In Thousands)

Parent	U.S. Guarantor Subsidiaries	Foreign Subsidiaries Non-Guarantors
--------	--------------------------------	---

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

Net sales	\$ 7,108	\$ 51,594	\$ 42,404
Cost of goods sold	5,632	41,161	33,848
Gross profit	1,476	10,433	8,556
Selling, general, and administrative expenses	3,737	8,542	6,777
Operating (loss) income	(2,261)	1,891	1,779
Interest expense	674	933	3,036
Interest income	3	--	(73)
Other expense (income)	117	19	(331)
Intercompany allocation	(993)	993	--
Loss (profit) relating to subsidiaries	1,098	--	--
(Loss) income before income taxes	(3,160)	(54)	(853)
(Benefit) provision for income taxes	(795)	320	(129)
Net (loss) income	\$ (2,365)	\$ (374)	\$ (724)

18

PHILIPP BROTHERS CHEMICALS INC.
 CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS (Unaudited)
 For the Three Months Ended September 30, 2001
 (In Thousands)

	Parent	U.S. Guarantor Subsidiaries	Foreign Subsidiaries Non-Guarantors
Operating activities:			
Net (loss) income	\$ (2,365)	\$ (374)	\$ (724)
Adjustments to reconcile net (loss) income to cash (used in) provided by operating activities:			
Depreciation and amortization	264	1,344	2,550
Other	(211)	65	935
Changes in operating assets and liabilities:			
Accounts receivable	210	2,369	2,946
Inventory	220	(1,401)	(3,202)
Prepaid expenses and other	362	1,843	401
Other assets	264	(996)	(83)
Intercompany	(3,000)	(718)	4,816
Accounts payable	(502)	(1,861)	1,029
Accrued expenses and other	1,462	1,093	(1,683)

18

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

Net cash (used in) provided by operating activities	(3,296)	1,364	6,985
Investing activities:			
Capital expenditures	(70)	(1,426)	(2,130)
Other investing	--	--	79
Net cash used in investing activities	(70)	(1,426)	(2,051)
Financing activities:			
Cash overdraft	--	246	(147)
Net increase (decrease) in short term debt	3,498	--	(1,581)
Proceeds from long term debt	--	11	--
Payments of long term debt	(8)	(126)	(939)
Net cash provided by (used in) financing activities	3,490	131	(2,667)
Effect of exchange rate changes on cash	--	--	52
Net increase in cash and cash equivalents	124	69	2,319
Cash and cash equivalents at beginning of year	1,292	700	12,853
Cash and cash equivalents at end of year	\$ 1,416	\$ 769	\$ 15,172

19

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

General

The Company is a leading diversified global manufacturer and marketer of a broad range of specialty agricultural and industrial chemicals, which are sold world-wide for use in numerous markets, including animal health and nutrition, agriculture, pharmaceutical, electronics, wood treatment, glass, construction and concrete. The Company also provides recycling and hazardous waste services primarily to the electronics and metal treatment industries. These operations are classified into four segments--Animal Health and Nutrition, Industrial Chemicals, Distribution and All Other.

The Company recorded operating income of \$4.4 million and \$1.4 million for the three months ended September 30, 2002 and 2001, respectively. Purchase accounting adjustments relating to inventory acquired in the acquisition of the Phibro Animal Health ("PAH") business in November 2002, resulted in an increase to cost of goods sold of \$2.0 million for the quarter ended September 30, 2001. Excluding the purchase accounting adjustment, the Company's performance in fiscal 2003 improved over the prior fiscal period.

At September 30, 2002, after giving effect to the amendment described

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

below, the Company was in compliance with the financial covenants included in its amended domestic senior credit facility ("credit agreement" or "credit facility") with its lending banks. During fiscal 2003, the Company amended the credit facility and obtained a waiver for noncompliance at June 30, 2002. In addition, the Company entered into an agreement with its Norwegian banks to restructure loans and to obtain a waiver for noncompliance at June 30, 2002. Further, the Company entered into an agreement with Pfizer whereby Pfizer agreed to defer until March 1, 2004, without interest, unpaid contingent purchase price amounts existing at May 31, 2002 and to waive contingent purchase price payments on future net revenues from June 1, 2002 through March 1, 2004.

In the first quarter of fiscal 2003, Odda reduced production of dicyandiamide pending market acceptance of its calcium oxide, a by-product of the manufacturing process. In November 2002, the Company announced a temporary shutdown of the Odda facility due to continuing operating losses, higher than planned operating costs and delays in the market acceptance of calcium oxide. Various alternatives are under consideration by the Company. Additional impairment charges may be recorded in the future, the extent of which will be dependent upon the outcome of the alternatives selected.

Certain prior year amounts have been reclassified to conform to the fiscal 2003 presentation. Freight and warehousing expenses of \$6,598 for the three months ended September 30, 2001 were reclassified from general and administrative expenses to cost of goods sold.

Results of Operations

	Sales (\$000's) Three Months Ended September 30,	
	2002	2001
Operating Segments:	-----	-----
Animal Health and Nutrition	\$ 60,903	\$ 59,353
Industrial Chemicals	20,215	21,011
Distribution	9,924	9,989
All Other	10,174	9,947
Elimination of intersegment sales	(4,175)	(5,641)
	-----	-----
	\$ 97,041	\$ 94,659
	=====	=====
	Operating Income (Loss) (\$000's) Three Months Ended September 30,	
	-----	-----
Operating Segments:	2002	2001
Animal Health and Nutrition	\$ 9,702	\$ 7,365
Industrial Chemicals	(2,110)	(4,200)
Distribution	743	838
All Other	85	119
Corporate expenses and intercompany profit elimination	(4,062)	(2,713)
	-----	-----
	\$ 4,358	\$ 1,409
	=====	=====

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

Comparison of Three Months Ended September 30, 2002 and 2001

Net Sales. Net sales increased by \$2.4 million, or 3%, to \$97.0 million in the three months ended September 30, 2002, as compared to the same period of the prior year. The increase was primarily due to higher sales in the Animal Health segment offset in part by declines in the Industrial Chemical segment.

The Animal Health and Nutrition segment's net sales increased by \$1.5 million, or 2.6% to \$60.9 million for the three months ended September 30, 2002. The Company's PAH operations improved due to higher unit volume sales of its antibacterial and anticoccidial products. Higher revenues were also recorded at the Company's Prince Agri operations due to higher unit volumes associated with its vitamin and other specialty ingredients. The Company's Koffolk sales declined due to the adverse business climate in Israel and unfavorable currency impacts at its Brazilian subsidiary.

The Industrial Chemicals segment's net sales decreased by \$.8 million, or 4%, to \$20.2 million in the three months ended September 30, 2002 as compared to the prior period. The Company's Odda subsidiary revenues declined by \$2.7 million due to discontinued production and sale of the CY-50 and calcium carbide product lines in the fourth quarter of 2002. In addition, in the quarter ended September 30, 2002, Odda reduced production of dicyandiamide pending market acceptance of its calcium oxide, a by-product of the manufacturing process. Sales by the Company's Phibro-Tech subsidiary increased by \$1.4 million due to increased unit volumes over the prior year comparable quarter. Higher unit shipments of pigments and blends and manganese dioxide products by the Company's Prince operations, partially offset by sales price declines, increased revenues by \$.5 million during the current fiscal period.

Net sales for the Distribution segment decreased by \$.1 million, or 1%, to \$9.9 million in 2002, as compared to the prior period. Declines in the segment's carbide sales, related to the discontinuance of carbide production at Odda, account for the decrease and were partially offset by improvements in product mix.

Net sales for the All Other segment increased by \$.2 million, or 2%, to \$10.2 million in 2002, as compared to the prior period. The Company's fly ash business increased revenues by approximately \$.8 million due to higher unit volumes offset in part by declines in average selling prices. A decrease in specialized lab projects and formulations at the segment's U.K. operations lowered revenues by \$.4 million. Lower sales of crop protection chemicals accounted for the balance of the decrease.

Gross Profit. Gross profit increased by \$1.3 million, or 7%, to \$21.8 million in the three months ended September 30, 2002, as compared to the prior period. Purchase accounting adjustments relating to inventory acquired in the PAH acquisition resulted in an increase to cost of goods sold of \$0 and \$2.0 million for the three months ended September 30, 2002 and 2001, respectively. Excluding the purchase accounting adjustments, gross profit increased by approximately \$.1 million in the Animal Health segment primarily due to higher unit volumes. The Industrial Chemicals segment increased by approximately \$.2 million primarily due to higher margins at the Company's Prince Manufacturing and Phibro-Tech facilities offset in part by higher production costs at the Company's Odda facility. The Distribution segment declined \$.1 million primarily as a result of lower unit volume of carbide products. The All Other segment declined by approximately \$.3 million primarily due to higher freight costs associated with the Company's fly ash operations and decreases in specialized lab projects and formulations at the segment's U.K. facility. Elimination of inter-company profit in inventory accounted for the balance of the decrease.

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

Selling, General and Administrative Expenses. Costs decreased by \$1.6 million, or 8% to \$17.4 million in 2002, as compared to the prior period. Costs declined primarily at the Company's Phibro-Tech, Koffolk and Odda operations due to cost reduction programs and lower levels of production activity. The prior period included a \$.4 million non-cash gain to reflect the decrease in repurchase value of redeemable common stock of a minority shareholder; no amount was recorded in the current period.

Operating Income (Loss). Operating income increased by \$2.9 million to \$4.4 million in 2002, as compared to the prior period. The Animal Health and Nutrition segment, after the exclusion of purchase accounting adjustments in fiscal 2002, increased due to higher unit volumes and cost reductions. The Industrial Chemicals segment improved primarily due to cost reduction programs and also higher sales and production volumes at the Company's Phibro-Tech facilities. The Company's Distribution and All Other segment declined slightly from the prior period.

Interest Expense, Net. Costs decreased by \$.2 million or 4% to \$4.4 million for the three months ended September 30, 2002 as compared to the prior period primarily due to lower interest rates offset in part by slightly higher average borrowing levels.

21

Other Expense, Net. Other expense, net principally reflects foreign currency transaction/translation gains and losses of the Company's foreign subsidiaries (principally Norwegian Kroner and the Israeli Shekel). The Company also recorded a gain of \$.7 million on a power purchase derivative instrument at its Odda facility.

Income Taxes. An income tax provision of \$.4 million was reported on a consolidated pre-tax income of \$.3 million in fiscal 2003 primarily due to income tax provisions in profitable foreign jurisdictions and also for state income taxes. In addition, domestic pre-tax income was recorded without a tax provision due to the utilization of net operating loss carryforwards with a full valuation allowance. The Company's Odda facility losses were not given any tax benefit. The Company's position with respect to the recoverability of these deferred tax assets will continue to be evaluated each reporting period based on actual and expected operating performance.

Liquidity and Capital Resources

Net Cash Provided by Operating Activities. Cash provided by operations for the three months ended September 30, 2002 and 2001 was \$24.8 million and \$5.1 million, respectively. Cash provided by operating activities increased in the three months ended September 30, 2002, compared with the three months ended September 30, 2001, primarily due to improved earnings and improvements in working capital management.

Net Cash Used in Investing Activities. Net cash used in investing activities for the three months ended September 30, 2002 and 2001 was \$3.7 million and \$3.5 million, respectively. Capital expenditures of \$4.0 million and \$3.6 million in the respective 2002 and 2001 periods, were mostly for new product development, maintaining the Company's existing asset base and for environmental, health and safety projects. Proceeds from the sale of assets accounted for the remainder of cash used in investing activities.

Net Cash (Used In) Provided by Financing Activities. Net cash (used in) provided by financing activities for the three months ended September 30, 2002 and 2001 was (\$17.9) million and \$1.0 million, respectively. Borrowings under

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

the domestic revolving credit agreement and other long-term debt were reduced in fiscal 2003 from cash generated by operating activities.

Liquidity. At September 30, 2002, after giving effect to the amendment referred to below, the Company was in compliance with the financial covenants included in its amended domestic senior credit facility ("credit agreement" or "credit facility") with its lending banks. The credit agreement was amended in October 2002 to: waive noncompliance with financial covenants as of June 30, 2002; amend financial covenants prospectively until maturity; amend the borrowing base formula and also reduce maximum availability under the revolving credit portion of the facility from \$70 million to \$55 million; limit borrowings under the capital expenditure line of the facility to the current outstanding balance of \$5.8 million; and revise the interest rate to 1.5% to 1.75% per annum over the base rate (as defined in the agreement). Management believes that the reduced maximum availability and the revised borrowing base formula under the revolving credit portion of the facility will not affect the Company's ability to meet its cash requirements during fiscal 2003.

The Company's ability to fund its fiscal 2003 operating plan relies upon continued availability of the credit agreement, which in turn, requires the Company to maintain compliance with the amended financial covenants. The financial covenants require certain ratios of consolidated interest coverage and a minimum level of domestic cash flows (each, as defined in the credit agreement). The Company believes it will be able to comply with the terms of the amended covenants based on its forecasted operating plan for fiscal 2003. In the event of adverse operating results and resultant violation of the covenants during 2003, the Company cannot be certain it will be able to obtain waivers or amendments on favorable terms, if at all.

In addition, the Company's credit agreement and its note payable to Pfizer mature in November 2003 and March 2004, respectively. The Company's management has undertaken actions to improve the Company's operating performance and overall liquidity in order to reduce debt levels and allow for ultimate refinancing of this debt in fiscal 2004. These actions include cost reduction activities, working capital improvement programs, shutdown of unprofitable operations, and possible sale of certain business operations and other assets. The Company has announced its intention to sell its Prince Manufacturing operations, part of the Prince Manufacturing Group, and also a U.K. operation which manufactures and sells chemical intermediates to the pharmaceutical industry. These actions are ongoing and will continue to be re-evaluated during fiscal 2003. In addition, the Company entered into an agreement with Pfizer whereby Pfizer agreed to defer until March 1, 2004, without interest, unpaid contingent purchase price amounts existing at May 31, 2002 and to waive contingent purchase price payments on future net revenues from June 1, 2002 through March 1, 2004.

As a result of the partial shutdown of Odda's operations and non-compliance with the financial covenants of its credit facilities, Odda has entered into an agreement with its Norwegian banks to restructure these loans and to obtain a waiver for the non-compliance. The agreement establishes a periodic payment schedule through November 30, 2003. Philipp Brothers Chemicals, Inc. is the guarantor of this debt.

Working capital as of September 30, 2002 was \$44.7 million compared to \$50.4 million at fiscal year end June 30, 2002. Due to the nature and terms of the credit agreement, which includes both a subjective acceleration clause and a requirement to maintain a lockbox arrangement, all borrowings against this facility are classified as a current liability. At September 30, 2002, the

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

amount of credit extended under this agreement totaled \$28.8 million and the Company had \$8.7 million available under the borrowing base formula in effect under this agreement. In addition, certain of the Company's foreign subsidiaries also had availability under their respective credit facilities totaling \$9.4 million. Management's efforts to improve liquidity has resulted in a decrease in borrowings under the revolving credit agreement to approximately \$24.7 million as of October 31, 2002.

The Company anticipates spending approximately \$10.7 million for capital expenditures in fiscal 2003, primarily to cover the Company's asset replacement needs, improve processes, and for environmental and regulatory compliance, subject to the availability of funds.

Critical Accounting Policies

The Securities and Exchange Commission ("SEC") recently issued disclosure guidance for "critical accounting policies". The SEC defines "critical accounting policies" as those that require application of management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods.

The Company's significant accounting policies are described in Note 1 to the Consolidated Financial Statements for the fiscal year ended June 30, 2002. Not all of these significant accounting policies require management to make difficult, subjective or complex judgments or estimates. However, management of the Company is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period they are determined to be necessary. Actual results could differ from those estimates. Following are some of the Company's critical accounting policies impacted by judgments, assumptions and estimates.

Revenue Recognition

Revenues are recognized when title to products and risk of loss are transferred to customers. Additional conditions for recognition of revenue are that collection of sales proceeds is reasonably assured and the Company has no further performance obligations. Net sales are comprised of total sales billed, net of goods returned, trade discounts and customer allowances.

Litigation

The Company is subject to legal proceedings and claims arising out of the normal course of business. The Company routinely assesses the likelihood of any adverse judgments or outcomes to these matters as well as ranges of probable losses. A determination of the amount of the reserves required for these contingencies is based on an analysis of the various issues, historical experience, other third party judgments and outside specialists, where required. The required reserves may change in the future due to new developments in each matter. For further discussion, see Note 13 to the Consolidated Financial Statements for the fiscal year ended June 30, 2002.

Environmental Matters

The Company determines the costs of environmental remediation of its facilities and formerly owned properties on the basis of current law and existing technologies. Uncertainties exist in these evaluations primarily due to

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

unknown conditions, changing governmental regulations and legal standards regarding liability, and evolving technologies. The liabilities are adjusted periodically as remediation efforts progress or as additional information becomes available. The Company has recorded liabilities of \$2.0 million at September 30, 2002 for such activities.

Long Lived Assets

Long-lived assets, including plant and equipment, and other intangible assets are reviewed for impairment when events or circumstances indicate that a diminution in value may have occurred, based on a comparison of undiscounted future cash flows to the carrying amount of the long-lived asset. If the carrying amount exceeds undiscounted future cash flows, an impairment charge is recorded based on the difference between the carrying amount of the asset and its fair value.

23

The assessment of potential impairment for a particular asset or set of assets requires certain judgments and estimates by the Company, including the determination of an event indicating impairment; the future cash flows to be generated by the asset, including the estimated life of the asset and likelihood of alternative courses of action; the risk associated with those cash flows; and the Company's cost of capital or discount rate to be utilized.

Useful Lives of Long-Lived Assets

Useful lives of long-lived assets, including plant and equipment and other intangible assets are based on management's estimates of the periods that the assets will be productively utilized in the revenue-generation process. Factors that affect the determination of lives include prior experience with similar assets and product life expectations and management's estimate of the period that the assets will generate revenue.

Inventories

Inventories are valued at the lower of cost or market. Cost is determined on a first-in, first-out (FIFO) and average methods for most inventories; however certain subsidiaries of the Company use the last-in, first-out (LIFO) method for valuing inventories. The determination of market value to compare to cost involves assessment of numerous factors, including costs to dispose of inventory and estimated selling prices. Reserves are recorded for inventory determined to be damaged, obsolete, or otherwise unsalable.

Income Taxes

Deferred tax assets and liabilities are determined using enacted tax rates for the effects of net operating losses and temporary differences between the book and tax bases of assets and liabilities. The Company records a valuation allowance on deferred tax assets when appropriate to reflect the expected future tax benefits to be realized. In determining the appropriate valuation allowance, certain judgments are made relating to recoverability of deferred tax assets, use of tax loss carryforwards, level of expected future taxable income and available tax planning strategies. These judgments are routinely reviewed by management.

New Accounting Pronouncements

In June 2002, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 146, "Accounting for Costs Associated with

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

Exit or Disposal Activities" ("SFAS No. 146"). SFAS No. 146 requires that a liability for a cost associated with an exit or disposal activity be recognized and measured initially at fair value when the liability is incurred rather than at the date of a commitment to an exit or disposal plan. Costs covered by SFAS No. 146 include lease termination costs and certain employee severance costs that are associated with a restructuring, discontinued operation, plant closing or other exit or disposal activity. SFAS No. 146 is effective for exit or disposal activities that are initiated after December 31, 2002. The Company is currently assessing the impact of this statement.

Seasonality of Business

There is some seasonality in the Company's results as sales of certain industrial chemicals to the wood treatment industry as well as sales of coal fly ash are typically highest during the peak construction periods of the first and fourth fiscal quarters.

Quantitative and Qualitative Disclosure About Market Risk

For financial market risks related to changes in interest rates, foreign currency exchange rates and commodity prices, reference is made to Part II, Item 7, Quantitative and Qualitative Disclosure About Market Risk, in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2002 and to Note 14 to the Consolidated Financial Statements of the Company included therein.

Certain Factors Affecting Future Operating Results

This Form 10-Q contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company's actual results could differ materially from those set forth in the forward-looking statements. Certain factors that might cause such a difference include, among other factors noted herein, the following: the Company's substantial leverage and potential inability to service its debt; the Company's dependence on distributions from its subsidiaries; risks associated with the Company's international

24

operations; the Company's dependence on its Israeli operations; competition in each of the Company's markets; potential environmental liability; extensive regulation by numerous government authorities in the United States and other countries; significant cyclical price fluctuation for the principal raw materials used by the Company in the manufacture of its products; the Company's reliance on the continued operation and sufficiency of its manufacturing facilities; the Company's dependence upon unpatented trade secrets; the risks of legal proceedings and general litigation expenses; potential operating hazards and uninsured risks; the risk of work stoppages; the Company's dependence on key personnel; and the uncertain impact of the Company's divestiture plans. See also the discussion under "Risks and Uncertainties" in Note 3 of the Notes to Condensed Consolidated Financial Statements included in this Report and matters referred to throughout Item 1 of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2002.

In addition, the issue of the potential for increased bacterial resistance to certain antibiotics used in certain food producing animals is the subject of discussions on a worldwide basis and, in certain instances, has led to government restrictions on the use of antibiotics in these food producing animals. The sale of feed additives containing antibiotics is a material portion of the Company's business. Should regulatory or other developments result in further restrictions on the sale of such products, it could have a material

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

adverse impact on the Company's financial position, results of operations and cash flows.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

See Part I -- Item 2 -- "Management's Discussion and Analysis of Financial Condition and Results of Operations -- Quantitative and Qualitative Disclosure About Market Risk."

Item 4. Control and Procedures

- (a) Based upon an evaluation by the Company's Chief Executive Officer, Chairman of the Board and Chief Financial Officer within 90 days prior to the filing date of this Quarterly Report on Form 10-Q they have concluded that the Company's disclosure controls and procedures as defined in Rule 15d-14(c) under the Securities Exchange Act of 1934, as amended, are effective for gathering, analyzing and disclosing information contained in the Company's periodic reports provided to the Securities and Exchange Commission.
- (b) Since the date of the most recent evaluation of the Company's internal controls, there have been no significant changes in such internal controls or in other factors that could significantly affect these controls nor were there any corrective actions with regard to significant deficiencies and material weaknesses.

25

PART II -- OTHER INFORMATION

Item 1. Legal Proceedings.

On or about April 17, 1997, Philipp Brothers Chemicals, Inc. ("Philipp Brothers") and CP Chemicals, Inc. ("CP") were served with a complaint filed by Chevron USA, Inc. ("Chevron") in the United States District Court for the District of New Jersey, alleging that operations of CP at its Sewaren plant affected adjoining property owned by Chevron and that Philipp Brothers, as the parent of CP, is also responsible to Chevron. In July 2002, a phased settlement agreement was reached under which the Company and another defendant will, subject to certain conditions, take title to the property, subject to a period of due diligence investigation of the property. The Company's portion of the settlement for past costs and expenses is \$495 and is included in selling, general and administrative expenses in the June 30, 2002 statement of operations and comprehensive income. The payable of \$495 is included in accrued expenses and other current liabilities as of June 30, 2002 and was subsequently paid in July 2002. The Company and the other defendant will, if the sale becomes final, share equally in the costs of remediation. While the costs cannot be estimated at this time, the Company believes the costs will not be material and insurance recoveries will be available to offset some of those costs.

Item 5. Other Information.

None.

Item 6. Exhibits and Reports on Form 8-K.

(a) Exhibits

Exhibit No.	Description
-----	-----

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

None.

(b) Reports on Form 8-K.

None.

26

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PHILIPP BROTHERS CHEMICALS, INC.

Date: November 14, 2002

By: /s/ JACK C. BENDHEIM

Jack C. Bendheim
Chairman of the Board

Date: November 14, 2002

By: /S/ GERALD K. CARLSON

Gerald K. Carlson
Chief Executive Officer

Date: November 14, 2002

By: /s/ RICHARD G. JOHNSON

Richard G. Johnson
Chief Financial Officer
(Principal Financial Officer and
Principal Accounting Officer)

27

CERTIFICATIONS

I, Gerald K. Carlson, certify that:

- (1) I have reviewed this quarterly report on Form 10-Q of Philipp Brothers Chemicals, Inc.;
- (2) Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
- (4) The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

have:

- a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
 - b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
 - c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
- (5) The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
- a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
- (6) The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: November 14, 2002

/s/ Gerald K. Carlson

Gerald K. Carlson,
Chief Executive Officer

28

I, Jack C. Bendheim, certify that:

- (1) I have reviewed this quarterly report on Form 10-Q of Philipp Brothers Chemicals, Inc.;
- (2) Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

- (4) The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
 - a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
 - b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
 - c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
- (5) The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
 - a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
- (6) The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: November 14, 2002

/s/ Jack C. Bendheim

Jack C. Bendheim,
Chairman of the Board

29

I, Richard G. Johnson, certify that:

- (1) I have reviewed this quarterly report on Form 10-Q of Philipp Brothers Chemicals, Inc.;
- (2) Based on my knowledge, this quarterly report does not contain any untrue

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

- (3) Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
- (4) The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
 - a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
 - b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
 - c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
- (5) The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
 - a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
- (6) The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: November 14, 2002

/s/ Richard G. Johnson

Richard G. Johnson,
Chief Financial Officer

Since the Company does not have securities registered under Section 12 of the Securities Exchange Act of 1934 and is not required to file periodic reports pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934, the

Edgar Filing: PHILIPP BROTHERS CHEMICALS INC - Form 10-Q

Company is not an "issuer" as defined in the Sarbanes-Oxley Act of 2002, and therefore the Company is not filing the written certification statement pursuant to Section 906 of such Act. The Company submits periodic reports with the Securities and Exchange Commission because it is required to do so by the terms of the indenture governing its senior subordinated notes.